A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and ...

PrEP reduces the risk of HIV, but current options need to be taken either daily in pill form or through an injection by a ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer ...

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its Codex® HiTemp Reverse Transcriptase for use in one ...

HIV works backward. Instead of DNA turning into RNA and making protein—the central dogma of biology—HIV uses the enzyme reverse transcriptase to turn viral RNA into DNA.

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase ...

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.

Clinical Significance of HIV Reverse-transcriptase Inhibitor-resistance Mutations Shiro Ibe; Wataru Sugiura Disclosures Future Microbiol. 2011;6 (3):295-315.

Read the latest data on resistance associated with reverse transcriptase inhibitors in these summaries from the 12th International HIV Drug Resistance Workshop.